 Robert Page
Concepts (652)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 34 | 2023 | 1945 | 4.340 |
Why?
| | Acute Coronary Syndrome | 8 | 2022 | 253 | 1.830 |
Why?
| | Immunosuppressive Agents | 10 | 2021 | 646 | 1.820 |
Why?
| | American Heart Association | 10 | 2022 | 264 | 1.670 |
Why?
| | Cardiovascular Agents | 7 | 2018 | 126 | 1.640 |
Why?
| | Health Resources | 4 | 2016 | 122 | 1.450 |
Why?
| | Medical Marijuana | 3 | 2021 | 97 | 1.420 |
Why?
| | Atrial Fibrillation | 15 | 2021 | 322 | 1.380 |
Why?
| | Stroke Volume | 8 | 2023 | 504 | 1.230 |
Why?
| | Anti-Arrhythmia Agents | 13 | 2014 | 106 | 1.150 |
Why?
| | Marijuana Smoking | 2 | 2021 | 224 | 1.130 |
Why?
| | Polypharmacy | 5 | 2023 | 74 | 1.120 |
Why?
| | Drug Interactions | 14 | 2021 | 338 | 1.050 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 287 | 1.040 |
Why?
| | Defibrillators, Implantable | 11 | 2001 | 286 | 1.010 |
Why?
| | Drug Overdose | 2 | 2022 | 292 | 0.990 |
Why?
| | Electric Countershock | 9 | 2001 | 104 | 0.970 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2022 | 238 | 0.940 |
Why?
| | Humans | 156 | 2023 | 114705 | 0.940 |
Why?
| | Heart Transplantation | 11 | 2017 | 665 | 0.910 |
Why?
| | Cost of Illness | 3 | 2014 | 254 | 0.880 |
Why?
| | Aminobutyrates | 1 | 2023 | 31 | 0.830 |
Why?
| | Opioid-Related Disorders | 2 | 2022 | 413 | 0.820 |
Why?
| | Cocaine | 2 | 2019 | 153 | 0.820 |
Why?
| | Health Expenditures | 2 | 2014 | 171 | 0.810 |
Why?
| | Arrhythmias, Cardiac | 9 | 2001 | 279 | 0.810 |
Why?
| | Theophylline | 1 | 2022 | 60 | 0.800 |
Why?
| | Drugs, Generic | 2 | 2020 | 18 | 0.790 |
Why?
| | Remote Consultation | 1 | 2022 | 42 | 0.790 |
Why?
| | Organ Transplantation | 2 | 2021 | 159 | 0.770 |
Why?
| | Graft Rejection | 4 | 2020 | 513 | 0.760 |
Why?
| | Propanolamines | 2 | 2019 | 90 | 0.730 |
Why?
| | Health Care Costs | 2 | 2014 | 381 | 0.720 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 373 | 0.710 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 3 | 2017 | 11 | 0.700 |
Why?
| | Drug Hypersensitivity | 5 | 2008 | 83 | 0.690 |
Why?
| | Aged | 52 | 2022 | 19074 | 0.680 |
Why?
| | Inpatients | 2 | 2016 | 380 | 0.670 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2011 | 144 | 0.650 |
Why?
| | Cardiovascular System | 1 | 2020 | 125 | 0.630 |
Why?
| | Anti-Infective Agents | 5 | 2010 | 225 | 0.630 |
Why?
| | Middle Aged | 60 | 2021 | 26738 | 0.620 |
Why?
| | Consensus | 2 | 2020 | 537 | 0.620 |
Why?
| | Marijuana Abuse | 1 | 2021 | 212 | 0.610 |
Why?
| | Cardiovascular Diseases | 7 | 2021 | 1727 | 0.600 |
Why?
| | Lung Transplantation | 1 | 2020 | 246 | 0.600 |
Why?
| | Hospitalization | 12 | 2023 | 1752 | 0.600 |
Why?
| | Male | 81 | 2021 | 55607 | 0.600 |
Why?
| | Prescription Drugs | 2 | 2016 | 116 | 0.590 |
Why?
| | Heart Rate | 16 | 2021 | 709 | 0.580 |
Why?
| | United States | 23 | 2022 | 12186 | 0.580 |
Why?
| | Tachycardia, Ventricular | 10 | 2001 | 152 | 0.560 |
Why?
| | Practice Patterns, Physicians' | 4 | 2022 | 1177 | 0.560 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2096 | 0.560 |
Why?
| | Sick Leave | 2 | 2014 | 12 | 0.560 |
Why?
| | Purines | 2 | 2022 | 159 | 0.550 |
Why?
| | Pregnancy Complications, Cardiovascular | 4 | 2001 | 64 | 0.550 |
Why?
| | Anticoagulants | 8 | 2021 | 550 | 0.550 |
Why?
| | Drug Monitoring | 5 | 2016 | 184 | 0.550 |
Why?
| | Chronic Disease | 8 | 2020 | 1578 | 0.540 |
Why?
| | Female | 74 | 2021 | 59521 | 0.530 |
Why?
| | Public Health | 1 | 2020 | 434 | 0.520 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 29 | 0.520 |
Why?
| | Treatment Outcome | 15 | 2023 | 9088 | 0.510 |
Why?
| | Ranolazine | 1 | 2015 | 22 | 0.510 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2016 | 76 | 0.500 |
Why?
| | Renin-Angiotensin System | 1 | 2016 | 72 | 0.500 |
Why?
| | Survival | 1 | 2015 | 37 | 0.500 |
Why?
| | Angina, Stable | 1 | 2015 | 17 | 0.500 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 38 | 0.500 |
Why?
| | Calcium Channel Blockers | 2 | 2015 | 114 | 0.490 |
Why?
| | Hospital Costs | 1 | 2016 | 104 | 0.490 |
Why?
| | Physical Therapy Specialty | 2 | 2006 | 34 | 0.490 |
Why?
| | Pyrazoles | 2 | 2022 | 362 | 0.480 |
Why?
| | Cardiac Pacing, Artificial | 9 | 2001 | 77 | 0.480 |
Why?
| | Patient Discharge | 6 | 2021 | 773 | 0.480 |
Why?
| | Employer Health Costs | 1 | 2014 | 4 | 0.480 |
Why?
| | Practice Guidelines as Topic | 4 | 2018 | 1395 | 0.470 |
Why?
| | Adult | 42 | 2020 | 30553 | 0.460 |
Why?
| | Vasodilator Agents | 5 | 2016 | 302 | 0.460 |
Why?
| | Electrocardiography | 18 | 2013 | 560 | 0.460 |
Why?
| | Patient Admission | 1 | 2016 | 176 | 0.460 |
Why?
| | Drug Utilization Review | 2 | 2006 | 57 | 0.450 |
Why?
| | Tacrolimus | 4 | 2016 | 134 | 0.450 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2023 | 179 | 0.450 |
Why?
| | Pain | 3 | 2022 | 705 | 0.440 |
Why?
| | Catheter Ablation | 6 | 2000 | 288 | 0.440 |
Why?
| | Hospital Mortality | 2 | 2016 | 776 | 0.430 |
Why?
| | Aged, 80 and over | 15 | 2021 | 6347 | 0.430 |
Why?
| | Muscular Diseases | 2 | 2019 | 104 | 0.430 |
Why?
| | Mortality | 1 | 2015 | 287 | 0.430 |
Why?
| | Sulfonamides | 5 | 2013 | 445 | 0.420 |
Why?
| | Daptomycin | 1 | 2013 | 18 | 0.420 |
Why?
| | Retrospective Studies | 18 | 2021 | 12556 | 0.420 |
Why?
| | Creatine Kinase | 1 | 2013 | 75 | 0.420 |
Why?
| | Drug Prescriptions | 3 | 2010 | 239 | 0.410 |
Why?
| | Platelet Aggregation Inhibitors | 4 | 2018 | 401 | 0.400 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 125 | 0.400 |
Why?
| | Pharmaceutical Services | 1 | 2013 | 77 | 0.400 |
Why?
| | Baroreflex | 5 | 2021 | 54 | 0.400 |
Why?
| | Models, Organizational | 1 | 2013 | 140 | 0.390 |
Why?
| | Pharmacy Service, Hospital | 4 | 2015 | 83 | 0.390 |
Why?
| | Hiccup | 1 | 2011 | 2 | 0.390 |
Why?
| | Cities | 1 | 2012 | 80 | 0.390 |
Why?
| | Medicaid | 1 | 2015 | 407 | 0.390 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2011 | 22 | 0.380 |
Why?
| | Ventricular Fibrillation | 4 | 2001 | 51 | 0.380 |
Why?
| | Amines | 1 | 2011 | 34 | 0.380 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2018 | 1183 | 0.380 |
Why?
| | Patient Education as Topic | 3 | 2013 | 680 | 0.370 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 5 | 2000 | 28 | 0.370 |
Why?
| | Atrioventricular Node | 4 | 1997 | 14 | 0.370 |
Why?
| | Myocardial Infarction | 3 | 2013 | 927 | 0.370 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 231 | 0.370 |
Why?
| | Medication Errors | 3 | 2013 | 88 | 0.370 |
Why?
| | Drug Substitution | 3 | 2020 | 46 | 0.360 |
Why?
| | Colorado | 9 | 2022 | 4100 | 0.360 |
Why?
| | Seizures | 2 | 2012 | 340 | 0.350 |
Why?
| | Adenosine | 3 | 2018 | 203 | 0.350 |
Why?
| | Transplant Recipients | 3 | 2017 | 140 | 0.350 |
Why?
| | Heart Conduction System | 9 | 2001 | 80 | 0.340 |
Why?
| | Electrocardiography, Ambulatory | 6 | 1999 | 54 | 0.340 |
Why?
| | Central Nervous System Agents | 1 | 2009 | 5 | 0.340 |
Why?
| | Aircraft | 3 | 2001 | 26 | 0.340 |
Why?
| | Health Services Accessibility | 1 | 2016 | 763 | 0.340 |
Why?
| | Clinical Protocols | 3 | 2017 | 233 | 0.330 |
Why?
| | Risk Factors | 11 | 2022 | 8632 | 0.330 |
Why?
| | Tobacco Smoke Pollution | 1 | 2012 | 217 | 0.320 |
Why?
| | Desensitization, Immunologic | 2 | 2008 | 117 | 0.320 |
Why?
| | Central Nervous System Diseases | 1 | 2009 | 61 | 0.320 |
Why?
| | Electrodes, Implanted | 4 | 1997 | 91 | 0.320 |
Why?
| | Premature Birth | 1 | 2012 | 276 | 0.310 |
Why?
| | Drug Costs | 2 | 2013 | 92 | 0.300 |
Why?
| | Cost Sharing | 1 | 2008 | 14 | 0.300 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2017 | 1842 | 0.300 |
Why?
| | Restless Legs Syndrome | 1 | 2008 | 19 | 0.300 |
Why?
| | Citalopram | 1 | 2008 | 27 | 0.300 |
Why?
| | Helicobacter Infections | 1 | 2007 | 25 | 0.290 |
Why?
| | Helicobacter pylori | 1 | 2007 | 30 | 0.290 |
Why?
| | Ticlopidine | 1 | 2008 | 55 | 0.290 |
Why?
| | Pacemaker, Artificial | 3 | 2001 | 106 | 0.290 |
Why?
| | Cardiology | 3 | 2023 | 259 | 0.290 |
Why?
| | Cyclosporine | 3 | 2010 | 161 | 0.280 |
Why?
| | Exanthema | 1 | 2008 | 74 | 0.280 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.280 |
Why?
| | Telemedicine | 1 | 2015 | 662 | 0.280 |
Why?
| | Tachycardia, Supraventricular | 6 | 2001 | 42 | 0.280 |
Why?
| | Prasugrel Hydrochloride | 2 | 2018 | 19 | 0.280 |
Why?
| | Analgesics | 1 | 2008 | 158 | 0.280 |
Why?
| | Managed Care Programs | 1 | 2008 | 133 | 0.280 |
Why?
| | Imidazolidines | 3 | 2001 | 8 | 0.280 |
Why?
| | Epistaxis | 1 | 2006 | 11 | 0.270 |
Why?
| | Comorbidity | 6 | 2016 | 1448 | 0.270 |
Why?
| | Warfarin | 4 | 2021 | 135 | 0.270 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2006 | 68 | 0.270 |
Why?
| | Health Behavior | 1 | 2012 | 704 | 0.260 |
Why?
| | Salvage Therapy | 1 | 2007 | 127 | 0.260 |
Why?
| | Fructose | 1 | 2006 | 100 | 0.260 |
Why?
| | Sympathetic Nervous System | 5 | 2001 | 171 | 0.250 |
Why?
| | Triazoles | 1 | 2007 | 131 | 0.250 |
Why?
| | Pharmacists | 3 | 2015 | 234 | 0.250 |
Why?
| | Imidazoles | 3 | 2001 | 208 | 0.250 |
Why?
| | Diabetic Neuropathies | 1 | 2006 | 79 | 0.250 |
Why?
| | Metronidazole | 1 | 2005 | 19 | 0.250 |
Why?
| | Models, Economic | 2 | 2016 | 48 | 0.240 |
Why?
| | Medication Adherence | 5 | 2018 | 536 | 0.240 |
Why?
| | Smoking | 1 | 2012 | 1383 | 0.240 |
Why?
| | Risk Assessment | 7 | 2022 | 2968 | 0.240 |
Why?
| | Thrombosis | 2 | 2021 | 298 | 0.240 |
Why?
| | Coronary Disease | 2 | 1998 | 348 | 0.240 |
Why?
| | Length of Stay | 3 | 2016 | 962 | 0.230 |
Why?
| | Piperazines | 3 | 2001 | 309 | 0.230 |
Why?
| | Young Adult | 7 | 2016 | 10471 | 0.230 |
Why?
| | Salaries and Fringe Benefits | 2 | 2014 | 52 | 0.220 |
Why?
| | Research Design | 1 | 2009 | 928 | 0.220 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2005 | 120 | 0.220 |
Why?
| | Metoprolol | 3 | 2001 | 37 | 0.220 |
Why?
| | Adolescent | 10 | 2016 | 17853 | 0.220 |
Why?
| | Cardiac Catheterization | 4 | 2008 | 534 | 0.210 |
Why?
| | Vagus Nerve | 2 | 1996 | 79 | 0.210 |
Why?
| | Dietary Supplements | 2 | 2010 | 460 | 0.210 |
Why?
| | Valsartan | 1 | 2023 | 22 | 0.210 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 467 | 0.210 |
Why?
| | Biphenyl Compounds | 1 | 2023 | 50 | 0.210 |
Why?
| | Pressoreceptors | 2 | 2021 | 18 | 0.200 |
Why?
| | Aminophylline | 1 | 2022 | 5 | 0.200 |
Why?
| | Time Factors | 9 | 2016 | 6116 | 0.200 |
Why?
| | Analgesics, Opioid | 2 | 2022 | 771 | 0.200 |
Why?
| | Sodium | 1 | 2023 | 183 | 0.200 |
Why?
| | Drug Therapy, Combination | 6 | 2016 | 951 | 0.200 |
Why?
| | Thiazolidinediones | 1 | 2003 | 142 | 0.200 |
Why?
| | Nitroprusside | 3 | 2016 | 64 | 0.200 |
Why?
| | Heart-Assist Devices | 2 | 2021 | 485 | 0.200 |
Why?
| | Prognosis | 6 | 2022 | 3330 | 0.200 |
Why?
| | Education, Pharmacy | 3 | 2016 | 123 | 0.200 |
Why?
| | Drug Combinations | 1 | 2023 | 287 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1214 | 0.200 |
Why?
| | Fluorobenzenes | 2 | 2013 | 11 | 0.200 |
Why?
| | Pharmacogenomic Testing | 2 | 2020 | 53 | 0.200 |
Why?
| | Troponin I | 2 | 2000 | 68 | 0.190 |
Why?
| | Anti-Bacterial Agents | 3 | 2013 | 1481 | 0.190 |
Why?
| | Students, Pharmacy | 2 | 2016 | 98 | 0.180 |
Why?
| | Azithromycin | 1 | 2001 | 80 | 0.180 |
Why?
| | Equipment Failure | 6 | 2001 | 106 | 0.180 |
Why?
| | Clinical Decision-Making | 2 | 2021 | 268 | 0.180 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 975 | 0.180 |
Why?
| | Hyperthermia, Induced | 7 | 2000 | 65 | 0.180 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 489 | 0.180 |
Why?
| | Policy Making | 1 | 2021 | 81 | 0.180 |
Why?
| | Prospective Studies | 8 | 2020 | 6220 | 0.170 |
Why?
| | Tachycardia, Paroxysmal | 3 | 1995 | 7 | 0.170 |
Why?
| | Blood Pressure | 6 | 2021 | 1538 | 0.170 |
Why?
| | Health Services Needs and Demand | 2 | 2016 | 243 | 0.170 |
Why?
| | Heart Arrest | 3 | 2001 | 293 | 0.170 |
Why?
| | Equipment Design | 6 | 2001 | 508 | 0.170 |
Why?
| | Health Personnel | 1 | 2005 | 574 | 0.170 |
Why?
| | Reflex, Abnormal | 1 | 1999 | 7 | 0.170 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 121 | 0.170 |
Why?
| | Drugs, Chinese Herbal | 1 | 1999 | 13 | 0.170 |
Why?
| | Geriatric Assessment | 2 | 2019 | 176 | 0.160 |
Why?
| | Cannabinoids | 1 | 2021 | 115 | 0.160 |
Why?
| | Canada | 1 | 2020 | 322 | 0.160 |
Why?
| | Coated Materials, Biocompatible | 1 | 1999 | 54 | 0.160 |
Why?
| | Pyrimidines | 2 | 2013 | 376 | 0.160 |
Why?
| | Glucose | 2 | 2023 | 897 | 0.160 |
Why?
| | Cardiologists | 1 | 2018 | 40 | 0.160 |
Why?
| | Heart Injuries | 1 | 1999 | 37 | 0.150 |
Why?
| | Ventricular Dysfunction, Left | 5 | 2020 | 358 | 0.150 |
Why?
| | Benzazepines | 1 | 2018 | 37 | 0.150 |
Why?
| | Monitoring, Ambulatory | 1 | 1999 | 81 | 0.150 |
Why?
| | Triazines | 1 | 1998 | 36 | 0.150 |
Why?
| | Heart Septal Defects, Atrial | 1 | 1998 | 51 | 0.150 |
Why?
| | Stevens-Johnson Syndrome | 1 | 1998 | 34 | 0.150 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 62 | 0.140 |
Why?
| | Dexamethasone | 1 | 1999 | 317 | 0.140 |
Why?
| | Clinical Competence | 4 | 2012 | 893 | 0.140 |
Why?
| | Patient Participation | 1 | 2020 | 359 | 0.140 |
Why?
| | Diuretics | 1 | 2017 | 66 | 0.140 |
Why?
| | Food, Fortified | 1 | 1997 | 36 | 0.140 |
Why?
| | Nutritional Physiological Phenomena | 1 | 1997 | 47 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2022 | 480 | 0.140 |
Why?
| | Hypoglycemic Agents | 2 | 2005 | 1013 | 0.140 |
Why?
| | Administration, Oral | 5 | 2021 | 728 | 0.140 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2016 | 38 | 0.130 |
Why?
| | Thiocyanates | 1 | 2016 | 29 | 0.130 |
Why?
| | Mexiletine | 1 | 2016 | 7 | 0.130 |
Why?
| | Amphetamine | 1 | 2016 | 22 | 0.130 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.130 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2006 | 39 | 0.130 |
Why?
| | Medication Reconciliation | 2 | 2013 | 25 | 0.130 |
Why?
| | HIV | 1 | 2017 | 208 | 0.130 |
Why?
| | Tetralogy of Fallot | 1 | 1997 | 81 | 0.130 |
Why?
| | Sex Factors | 3 | 2015 | 1715 | 0.130 |
Why?
| | Neural Tube Defects | 1 | 1997 | 61 | 0.130 |
Why?
| | Intensive Care Units | 3 | 2019 | 617 | 0.130 |
Why?
| | Ventricular Function | 1 | 1996 | 57 | 0.130 |
Why?
| | Anticonvulsants | 1 | 1998 | 179 | 0.130 |
Why?
| | Follow-Up Studies | 7 | 2015 | 4411 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 61 | 0.130 |
Why?
| | Amiodarone | 3 | 2001 | 23 | 0.130 |
Why?
| | Rosuvastatin Calcium | 2 | 2013 | 17 | 0.130 |
Why?
| | Folic Acid | 1 | 1997 | 161 | 0.130 |
Why?
| | Patient Readmission | 3 | 2021 | 610 | 0.130 |
Why?
| | Substance Abuse Detection | 1 | 2016 | 62 | 0.130 |
Why?
| | Patient Safety | 2 | 2016 | 277 | 0.130 |
Why?
| | Nitroglycerin | 1 | 2015 | 19 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 68 | 0.130 |
Why?
| | Certification | 2 | 2006 | 89 | 0.130 |
Why?
| | Anti-Retroviral Agents | 1 | 2017 | 207 | 0.120 |
Why?
| | Prevalence | 3 | 2023 | 2251 | 0.120 |
Why?
| | Societies, Pharmaceutical | 2 | 2013 | 27 | 0.120 |
Why?
| | Pre-Excitation Syndromes | 1 | 1995 | 4 | 0.120 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 544 | 0.120 |
Why?
| | Quality Improvement | 3 | 2020 | 950 | 0.120 |
Why?
| | Age Distribution | 1 | 2015 | 342 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2016 | 154 | 0.120 |
Why?
| | Insurance, Disability | 1 | 2014 | 1 | 0.120 |
Why?
| | Exercise Test | 2 | 2021 | 544 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 207 | 0.120 |
Why?
| | Health Services | 1 | 2015 | 103 | 0.120 |
Why?
| | Antidotes | 1 | 2016 | 135 | 0.120 |
Why?
| | Soft Tissue Neoplasms | 4 | 2000 | 90 | 0.120 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 51 | 0.120 |
Why?
| | Comparative Effectiveness Research | 1 | 2015 | 130 | 0.120 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2005 | 348 | 0.120 |
Why?
| | Life Style | 2 | 2018 | 430 | 0.120 |
Why?
| | Hemorrhage | 4 | 2021 | 620 | 0.120 |
Why?
| | Absenteeism | 1 | 2014 | 40 | 0.120 |
Why?
| | Risk | 2 | 2017 | 812 | 0.120 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 4624 | 0.110 |
Why?
| | Insurance Claim Review | 1 | 2014 | 67 | 0.110 |
Why?
| | Efficiency | 1 | 2014 | 84 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2014 | 196 | 0.110 |
Why?
| | Databases, Factual | 2 | 2018 | 1125 | 0.110 |
Why?
| | Mass Casualty Incidents | 1 | 2014 | 38 | 0.110 |
Why?
| | Homicide | 1 | 2014 | 53 | 0.110 |
Why?
| | Torsades de Pointes | 1 | 2013 | 17 | 0.110 |
Why?
| | Linear Models | 1 | 2016 | 768 | 0.110 |
Why?
| | Blood Pressure Determination | 1 | 2014 | 122 | 0.110 |
Why?
| | Pregnancy | 5 | 2012 | 5520 | 0.110 |
Why?
| | Procainamide | 1 | 1993 | 5 | 0.110 |
Why?
| | Medicare | 2 | 2015 | 665 | 0.110 |
Why?
| | Blood Coagulation | 1 | 2014 | 218 | 0.100 |
Why?
| | Calcineurin Inhibitors | 2 | 2010 | 58 | 0.100 |
Why?
| | Long QT Syndrome | 1 | 2013 | 59 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2005 | 2128 | 0.100 |
Why?
| | Simvastatin | 1 | 2013 | 59 | 0.100 |
Why?
| | Medical Staff | 1 | 2012 | 16 | 0.100 |
Why?
| | Regression Analysis | 5 | 2016 | 945 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1430 | 0.100 |
Why?
| | Critical Care | 2 | 2016 | 476 | 0.100 |
Why?
| | Dog Diseases | 4 | 1999 | 41 | 0.100 |
Why?
| | Adenosine A2 Receptor Antagonists | 1 | 2012 | 10 | 0.100 |
Why?
| | Physicians | 1 | 2020 | 772 | 0.100 |
Why?
| | Chronic Pain | 1 | 2015 | 210 | 0.100 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 115 | 0.100 |
Why?
| | Hemodynamics | 4 | 2021 | 1012 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2015 | 3003 | 0.100 |
Why?
| | Models, Educational | 1 | 2012 | 84 | 0.100 |
Why?
| | Residence Characteristics | 2 | 2012 | 275 | 0.100 |
Why?
| | Phenylephrine | 3 | 1999 | 71 | 0.100 |
Why?
| | Maternal Age | 1 | 2012 | 117 | 0.100 |
Why?
| | Bisoprolol | 1 | 2011 | 4 | 0.100 |
Why?
| | Health Policy | 2 | 2011 | 334 | 0.090 |
Why?
| | Foundations | 1 | 2011 | 22 | 0.090 |
Why?
| | Infant, Small for Gestational Age | 1 | 2012 | 76 | 0.090 |
Why?
| | Sinoatrial Node | 1 | 1991 | 27 | 0.090 |
Why?
| | Health Services Misuse | 2 | 2020 | 36 | 0.090 |
Why?
| | Wounds, Gunshot | 1 | 2014 | 193 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 38 | 0.090 |
Why?
| | Carbazoles | 1 | 2011 | 78 | 0.090 |
Why?
| | Research Report | 1 | 2011 | 75 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 493 | 0.090 |
Why?
| | Drug Information Services | 2 | 2013 | 9 | 0.090 |
Why?
| | Piperidines | 1 | 1992 | 160 | 0.090 |
Why?
| | Contraindications | 2 | 2002 | 85 | 0.090 |
Why?
| | Acute Disease | 2 | 2018 | 911 | 0.090 |
Why?
| | Primary Prevention | 2 | 2010 | 172 | 0.090 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2015 | 444 | 0.090 |
Why?
| | Heart Atria | 3 | 2000 | 107 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 486 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1352 | 0.080 |
Why?
| | Depressive Disorder | 1 | 2012 | 332 | 0.080 |
Why?
| | Complementary Therapies | 1 | 2010 | 72 | 0.080 |
Why?
| | Quality Assurance, Health Care | 2 | 2013 | 311 | 0.080 |
Why?
| | Delphi Technique | 1 | 2009 | 160 | 0.080 |
Why?
| | Cohort Studies | 2 | 2016 | 4895 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 1880 | 0.080 |
Why?
| | Pregabalin | 1 | 2008 | 9 | 0.080 |
Why?
| | Biological Products | 1 | 2011 | 166 | 0.080 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 2008 | 15 | 0.080 |
Why?
| | Patient Care Team | 1 | 2013 | 517 | 0.080 |
Why?
| | Monoamine Oxidase | 1 | 2008 | 27 | 0.080 |
Why?
| | Antiparkinson Agents | 1 | 2008 | 26 | 0.080 |
Why?
| | Cardiomyopathies | 3 | 2017 | 298 | 0.080 |
Why?
| | Pharmacogenetics | 2 | 2020 | 149 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2010 | 362 | 0.080 |
Why?
| | Age Factors | 3 | 2009 | 2894 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 590 | 0.080 |
Why?
| | Benchmarking | 2 | 2023 | 161 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2016 | 947 | 0.070 |
Why?
| | Hypertension | 2 | 2014 | 1056 | 0.070 |
Why?
| | Omeprazole | 1 | 2007 | 5 | 0.070 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2008 | 23 | 0.070 |
Why?
| | Professional Role | 2 | 2006 | 149 | 0.070 |
Why?
| | Conflict of Interest | 1 | 2009 | 119 | 0.070 |
Why?
| | Amoxicillin | 1 | 2007 | 20 | 0.070 |
Why?
| | Levofloxacin | 1 | 2007 | 22 | 0.070 |
Why?
| | Ofloxacin | 1 | 2007 | 22 | 0.070 |
Why?
| | Vascular Diseases | 1 | 2010 | 230 | 0.070 |
Why?
| | Societies, Medical | 1 | 2011 | 664 | 0.070 |
Why?
| | Cardiotonic Agents | 2 | 1999 | 119 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2017 | 4410 | 0.070 |
Why?
| | Peer Review, Research | 1 | 2008 | 34 | 0.070 |
Why?
| | Drug-Eluting Stents | 1 | 2008 | 62 | 0.070 |
Why?
| | Injections, Intravenous | 2 | 2001 | 198 | 0.070 |
Why?
| | Atrial Function | 2 | 1999 | 11 | 0.070 |
Why?
| | Mucor | 1 | 2007 | 7 | 0.070 |
Why?
| | Atrial Flutter | 3 | 2000 | 25 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 76 | 0.070 |
Why?
| | Hydrochlorothiazide | 1 | 2006 | 8 | 0.070 |
Why?
| | Hydantoins | 3 | 2001 | 5 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 42 | 0.070 |
Why?
| | Registries | 1 | 2014 | 1768 | 0.070 |
Why?
| | Neuralgia | 1 | 2008 | 122 | 0.070 |
Why?
| | Angioedema | 1 | 2006 | 15 | 0.070 |
Why?
| | Proton Pump Inhibitors | 1 | 2007 | 96 | 0.070 |
Why?
| | Clinical Trials as Topic | 4 | 2010 | 932 | 0.070 |
Why?
| | Disease Management | 2 | 2021 | 560 | 0.070 |
Why?
| | Metabolic Clearance Rate | 2 | 2005 | 102 | 0.070 |
Why?
| | Antidepressive Agents | 2 | 2005 | 195 | 0.070 |
Why?
| | Alcohol Drinking | 1 | 2012 | 651 | 0.070 |
Why?
| | Antihypertensive Agents | 2 | 2006 | 429 | 0.070 |
Why?
| | Professional Autonomy | 1 | 2006 | 25 | 0.060 |
Why?
| | Curriculum | 2 | 2016 | 819 | 0.060 |
Why?
| | Preceptorship | 1 | 2006 | 62 | 0.060 |
Why?
| | Drug Utilization | 1 | 2006 | 167 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 39 | 0.060 |
Why?
| | Pharmaceutical Preparations | 1 | 2008 | 165 | 0.060 |
Why?
| | Combined Modality Therapy | 5 | 2000 | 1121 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 172 | 0.060 |
Why?
| | Medical History Taking | 1 | 2006 | 114 | 0.060 |
Why?
| | Disease-Free Survival | 1 | 2007 | 620 | 0.060 |
Why?
| | Norepinephrine | 3 | 2021 | 201 | 0.060 |
Why?
| | Biotransformation | 1 | 2005 | 48 | 0.060 |
Why?
| | Pancreatitis | 1 | 2005 | 107 | 0.060 |
Why?
| | Incidence | 3 | 2023 | 2313 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 916 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 108 | 0.060 |
Why?
| | Educational Measurement | 1 | 2006 | 243 | 0.060 |
Why?
| | Odds Ratio | 1 | 2006 | 953 | 0.060 |
Why?
| | Parkinson Disease | 1 | 2008 | 345 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2000 | 478 | 0.060 |
Why?
| | Biological Transport | 1 | 2005 | 374 | 0.060 |
Why?
| | Educational Status | 1 | 2006 | 412 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2006 | 583 | 0.060 |
Why?
| | Reflex | 2 | 1996 | 64 | 0.050 |
Why?
| | Decision Making | 2 | 2019 | 782 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 377 | 0.050 |
Why?
| | Creatinine | 1 | 2005 | 425 | 0.050 |
Why?
| | HIV Infections | 1 | 2017 | 2469 | 0.050 |
Why?
| | Mass Screening | 1 | 2010 | 1006 | 0.050 |
Why?
| | Peroneal Nerve | 2 | 2001 | 19 | 0.050 |
Why?
| | Dogs | 8 | 2000 | 334 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 371 | 0.050 |
Why?
| | Myocardial Ischemia | 2 | 2001 | 235 | 0.050 |
Why?
| | Health Status | 1 | 2008 | 722 | 0.050 |
Why?
| | Recurrence | 3 | 2001 | 935 | 0.050 |
Why?
| | Paget Disease, Extramammary | 1 | 2002 | 3 | 0.050 |
Why?
| | Depression | 2 | 2008 | 1134 | 0.050 |
Why?
| | Sarcoma | 2 | 1994 | 137 | 0.050 |
Why?
| | Facial Neoplasms | 1 | 2002 | 17 | 0.050 |
Why?
| | Patient Selection | 1 | 2006 | 641 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 607 | 0.050 |
Why?
| | Drug Therapy | 1 | 2002 | 76 | 0.050 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 668 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2012 | 5047 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 280 | 0.050 |
Why?
| | Electrophysiology | 3 | 2000 | 201 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.050 |
Why?
| | Action Potentials | 3 | 2000 | 406 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2006 | 635 | 0.050 |
Why?
| | Axilla | 1 | 2001 | 39 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2001 | 29 | 0.050 |
Why?
| | Sodium Channel Blockers | 1 | 2001 | 23 | 0.050 |
Why?
| | Qualitative Research | 1 | 2006 | 936 | 0.050 |
Why?
| | Survival Rate | 2 | 2004 | 1644 | 0.040 |
Why?
| | Bundle of His | 1 | 2000 | 14 | 0.040 |
Why?
| | Volunteers | 1 | 2000 | 31 | 0.040 |
Why?
| | Retreatment | 1 | 2000 | 67 | 0.040 |
Why?
| | Shoulder | 1 | 2001 | 85 | 0.040 |
Why?
| | Bundle-Branch Block | 1 | 2000 | 28 | 0.040 |
Why?
| | Parasympathectomy | 1 | 2000 | 1 | 0.040 |
Why?
| | United States Food and Drug Administration | 2 | 2001 | 172 | 0.040 |
Why?
| | Weight Loss | 1 | 2005 | 642 | 0.040 |
Why?
| | Sarcoma, Experimental | 1 | 2000 | 5 | 0.040 |
Why?
| | Thromboembolism | 1 | 2021 | 92 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1140 | 0.040 |
Why?
| | Tilt-Table Test | 1 | 1999 | 6 | 0.040 |
Why?
| | Maximum Allowable Concentration | 1 | 1999 | 14 | 0.040 |
Why?
| | Angelica sinensis | 1 | 1999 | 2 | 0.040 |
Why?
| | Multimorbidity | 1 | 2019 | 33 | 0.040 |
Why?
| | Cisplatin | 2 | 1993 | 262 | 0.040 |
Why?
| | Prothrombin Time | 1 | 1999 | 34 | 0.040 |
Why?
| | Thoracotomy | 2 | 1997 | 75 | 0.040 |
Why?
| | International Normalized Ratio | 1 | 1999 | 45 | 0.040 |
Why?
| | Transitional Care | 1 | 2019 | 34 | 0.040 |
Why?
| | Electromagnetic Fields | 1 | 1999 | 21 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2005 | 541 | 0.040 |
Why?
| | Data Display | 1 | 1999 | 19 | 0.040 |
Why?
| | Abnormalities, Drug-Induced | 1 | 1999 | 10 | 0.040 |
Why?
| | Telephone | 3 | 1995 | 153 | 0.040 |
Why?
| | Rhabdomyolysis | 1 | 2019 | 16 | 0.040 |
Why?
| | Intraoperative Period | 1 | 1999 | 51 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2000 | 1342 | 0.040 |
Why?
| | Child | 3 | 2015 | 18420 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2000 | 222 | 0.040 |
Why?
| | Delirium | 1 | 2019 | 66 | 0.040 |
Why?
| | Drug Synergism | 1 | 1999 | 317 | 0.040 |
Why?
| | Echocardiography | 2 | 1998 | 553 | 0.040 |
Why?
| | Heart Diseases | 2 | 2005 | 331 | 0.040 |
Why?
| | Heart Ventricles | 2 | 2000 | 712 | 0.040 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 20 | 0.040 |
Why?
| | Hydrogen | 1 | 1998 | 59 | 0.040 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 96 | 0.040 |
Why?
| | Resuscitation | 1 | 2000 | 252 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2016 | 2765 | 0.040 |
Why?
| | Signal Transduction | 1 | 2010 | 4516 | 0.040 |
Why?
| | Maternal-Fetal Exchange | 1 | 1999 | 151 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2000 | 217 | 0.040 |
Why?
| | Heart Block | 1 | 1997 | 38 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 1994 | 473 | 0.040 |
Why?
| | Digoxin | 1 | 1997 | 26 | 0.040 |
Why?
| | Frailty | 1 | 2019 | 115 | 0.040 |
Why?
| | Bread | 1 | 1997 | 4 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1998 | 284 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 1994 | 167 | 0.040 |
Why?
| | Energy Intake | 1 | 2019 | 427 | 0.030 |
Why?
| | Edible Grain | 1 | 1997 | 43 | 0.030 |
Why?
| | Body Surface Area | 1 | 1997 | 27 | 0.030 |
Why?
| | Anesthetics | 1 | 2017 | 54 | 0.030 |
Why?
| | Propensity Score | 1 | 2018 | 224 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1998 | 641 | 0.030 |
Why?
| | Nutritional Requirements | 1 | 1997 | 75 | 0.030 |
Why?
| | Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 5 | 0.030 |
Why?
| | Chromatography, Gas | 1 | 2016 | 27 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 462 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1997 | 250 | 0.030 |
Why?
| | Electric Conductivity | 1 | 1996 | 88 | 0.030 |
Why?
| | Perioperative Care | 1 | 2017 | 127 | 0.030 |
Why?
| | Surface Properties | 1 | 1997 | 387 | 0.030 |
Why?
| | Diabetes Mellitus | 2 | 2019 | 900 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 385 | 0.030 |
Why?
| | Precision Medicine | 1 | 2018 | 337 | 0.030 |
Why?
| | Forecasting | 1 | 1997 | 330 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1996 | 126 | 0.030 |
Why?
| | Preoperative Care | 1 | 2017 | 319 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 24 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 2016 | 139 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 514 | 0.030 |
Why?
| | Animals | 10 | 2010 | 31709 | 0.030 |
Why?
| | PubMed | 1 | 2013 | 10 | 0.030 |
Why?
| | Stochastic Processes | 1 | 1994 | 64 | 0.030 |
Why?
| | Medical Assistance | 1 | 2013 | 13 | 0.030 |
Why?
| | Disaster Planning | 1 | 2014 | 74 | 0.030 |
Why?
| | Acecainide | 1 | 1993 | 1 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 224 | 0.030 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2013 | 21 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1994 | 305 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 1995 | 248 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 1993 | 79 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 512 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2013 | 79 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 371 | 0.030 |
Why?
| | Stroke | 1 | 2021 | 1022 | 0.030 |
Why?
| | Program Development | 1 | 2014 | 341 | 0.030 |
Why?
| | Medication Therapy Management | 1 | 2013 | 67 | 0.020 |
Why?
| | Kidney | 1 | 2019 | 1188 | 0.020 |
Why?
| | Program Evaluation | 1 | 2016 | 822 | 0.020 |
Why?
| | Biological Availability | 1 | 1992 | 119 | 0.020 |
Why?
| | Education | 1 | 2012 | 95 | 0.020 |
Why?
| | History, 21st Century | 1 | 2012 | 159 | 0.020 |
Why?
| | Therapeutic Equivalency | 1 | 2011 | 18 | 0.020 |
Why?
| | Internationality | 1 | 2012 | 143 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 1999 | 979 | 0.020 |
Why?
| | Self Care | 1 | 2014 | 349 | 0.020 |
Why?
| | Urinary Retention | 1 | 2011 | 19 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 264 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 1995 | 340 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1760 | 0.020 |
Why?
| | Random Allocation | 1 | 1992 | 335 | 0.020 |
Why?
| | Ovarian Neoplasms | 2 | 1993 | 388 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 646 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1637 | 0.020 |
Why?
| | Body Temperature | 1 | 1992 | 208 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1992 | 151 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 490 | 0.020 |
Why?
| | Biomarkers | 2 | 2016 | 3408 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 88 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2387 | 0.020 |
Why?
| | Reference Values | 1 | 1991 | 743 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 578 | 0.020 |
Why?
| | Terminal Care | 1 | 2012 | 213 | 0.020 |
Why?
| | Micronutrients | 1 | 2010 | 78 | 0.020 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2009 | 28 | 0.020 |
Why?
| | Heart | 2 | 1995 | 612 | 0.020 |
Why?
| | Journal Impact Factor | 1 | 2009 | 27 | 0.020 |
Why?
| | Food | 1 | 2010 | 160 | 0.020 |
Why?
| | Double-Blind Method | 1 | 1992 | 1660 | 0.020 |
Why?
| | Tricuspid Valve | 1 | 1987 | 25 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2012 | 573 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 808 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2286 | 0.020 |
Why?
| | Internship, Nonmedical | 1 | 2006 | 18 | 0.020 |
Why?
| | Specialty Boards | 1 | 2006 | 32 | 0.020 |
Why?
| | Cross Reactions | 1 | 2006 | 117 | 0.020 |
Why?
| | Schools, Pharmacy | 1 | 2006 | 48 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 1994 | 3053 | 0.020 |
Why?
| | Temperature | 3 | 1999 | 565 | 0.020 |
Why?
| | Probability | 1 | 2006 | 289 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2000 | 511 | 0.020 |
Why?
| | Faculty | 1 | 2006 | 130 | 0.020 |
Why?
| | Furosemide | 1 | 2005 | 32 | 0.020 |
Why?
| | Molecular Structure | 1 | 2006 | 434 | 0.020 |
Why?
| | Antimetabolites | 1 | 2004 | 21 | 0.020 |
Why?
| | Growth Inhibitors | 1 | 2004 | 43 | 0.020 |
Why?
| | Azathioprine | 1 | 2004 | 49 | 0.010 |
Why?
| | Everolimus | 1 | 2004 | 61 | 0.010 |
Why?
| | Diphosphonates | 1 | 2005 | 51 | 0.010 |
Why?
| | Gout | 1 | 2005 | 36 | 0.010 |
Why?
| | Blood Glucose | 1 | 1993 | 1828 | 0.010 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 77 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2005 | 86 | 0.010 |
Why?
| | Hyperlipidemias | 1 | 2005 | 121 | 0.010 |
Why?
| | Sirolimus | 1 | 2004 | 181 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1820 | 0.010 |
Why?
| | Infection Control | 1 | 2005 | 135 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1470 | 0.010 |
Why?
| | Myocardial Contraction | 2 | 1999 | 313 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2005 | 213 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 797 | 0.010 |
Why?
| | Protein Kinases | 1 | 2004 | 307 | 0.010 |
Why?
| | Nutritional Status | 1 | 2005 | 287 | 0.010 |
Why?
| | Cheek | 1 | 2002 | 16 | 0.010 |
Why?
| | Mohs Surgery | 1 | 2002 | 24 | 0.010 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 360 | 0.010 |
Why?
| | Legislation, Medical | 1 | 2001 | 10 | 0.010 |
Why?
| | Device Approval | 1 | 2001 | 21 | 0.010 |
Why?
| | Osteoporosis | 1 | 2005 | 226 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2004 | 497 | 0.010 |
Why?
| | Partial Pressure | 1 | 2000 | 30 | 0.010 |
Why?
| | Parasympathetic Nervous System | 1 | 2000 | 24 | 0.010 |
Why?
| | Central Venous Pressure | 1 | 1999 | 12 | 0.010 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 1999 | 9 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 289 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 785 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 1999 | 244 | 0.010 |
Why?
| | Epinephrine | 1 | 2000 | 164 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 89 | 0.010 |
Why?
| | Biopsy | 1 | 2002 | 1036 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 387 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1211 | 0.010 |
Why?
| | Cutaneous Fistula | 1 | 1995 | 13 | 0.010 |
Why?
| | Oxygen | 1 | 2000 | 854 | 0.010 |
Why?
| | Foreign Bodies | 1 | 1995 | 96 | 0.010 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 5 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1993 | 23 | 0.010 |
Why?
| | Infusions, Parenteral | 1 | 1993 | 36 | 0.010 |
Why?
| | Half-Life | 1 | 1993 | 141 | 0.010 |
Why?
| | Intracellular Fluid | 1 | 1993 | 27 | 0.010 |
Why?
| | Microelectrodes | 1 | 1993 | 32 | 0.010 |
Why?
| | Wolff-Parkinson-White Syndrome | 1 | 1993 | 16 | 0.010 |
Why?
| | Extracellular Space | 1 | 1993 | 116 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1995 | 249 | 0.010 |
Why?
| | Phosphates | 1 | 1994 | 159 | 0.010 |
Why?
| | Survivors | 1 | 1996 | 411 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1992 | 56 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1995 | 1075 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1993 | 424 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1994 | 430 | 0.010 |
Why?
| | Hepatitis, Animal | 1 | 1987 | 2 | 0.000 |
Why?
| | Endocardium | 1 | 1987 | 30 | 0.000 |
Why?
| | Injections, Intraperitoneal | 1 | 1987 | 99 | 0.000 |
Why?
| | Tachycardia | 1 | 1987 | 50 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1987 | 286 | 0.000 |
Why?
| | Peritonitis | 1 | 1987 | 77 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1987 | 161 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1987 | 1016 | 0.000 |
Why?
| | Lymph Nodes | 1 | 1987 | 419 | 0.000 |
Why?
| | Pulmonary Fibrosis | 1 | 1987 | 323 | 0.000 |
Why?
| | Child, Preschool | 1 | 1994 | 9118 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1987 | 3535 | 0.000 |
Why?
|
|
Page's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|